Overview

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Status:
Completed
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).
Phase:
Phase 2
Details
Lead Sponsor:
Galapagos NV